UroMed Gets FDA Approval For Radioactive Seed
WESTPORT, May 19 (Reuters Health) - UroMed Corp. announced on
Tuesday that the Food and drug Administration has approved for
marketing the company's Symmetra I-125 brachytherapy seed for
prostate cancer radiation seed implant procedures. According to
a UroMed statement, the company expects to begin shipping the
seeds within the next 60 days.
God Bless All,
marty auslander
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
